scholarly journals Empowering Mayo Clinic Individualized Medicine with Genomic Data Warehousing

2017 ◽  
Vol 7 (3) ◽  
pp. 7 ◽  
Author(s):  
Iain Horton ◽  
Yaxiong Lin ◽  
Gay Reed ◽  
Mathieu Wiepert ◽  
Steven Hart
Keyword(s):  
Mayo Clinic ◽  
Data Warehousing ◽  
Individualized Medicine ◽  
Genomic Data

Clinical utility of molecular testing to select therapy in relapsed/refractory non-Hodgkin lymphoma: Mayo Clinic Center for Individualized Medicine experience.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11571-11571
Author(s):  
Nabila Nora Bennani ◽  
Stephen Maxted Ansell ◽  
Thomas E. Witzig ◽  
Andew L. Feldman ◽  
Tammy M McAllister ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Targeted Therapy ◽  
Precision Medicine ◽  
Mayo Clinic ◽  
Individualized Medicine ◽  
Tumor Board ◽  
Current Therapy ◽  
Molecular Profile ◽  
Molecular Testing ◽  
Molecular Alterations

11571 Background: Relapsed/refractory (R/R) non-Hodgkin lymphomas (NHL) have a poor prognosis with limited treatment options. Our expanding knowledge of molecular alterations seen in R/R NHL allows identification of patients that potentially may benefit from a precision medicine approach. However, experience in routine clinical implementation of precision medicine has been limited. Here, we summarize our clinical experience in molecular characterization of RR NHL targeted therapy (TT) using next-generation sequencing (NGS), and selection of targeted therapy (TT) based on molecular profile. Methods: We conducted a prospective study in RR NHL through the Center for Individualized Medicine at Mayo Clinic. Consenting patients underwent NGS using FoundationOne Heme panel from biopsies done at time of relapse. Results of NGS were discussed at the Genomic Tumor Board and recommendations for TT were given based on matching specific molecular alteration(s) with potential agent(s) predicted to be active based on NGS. The agents could include FDA-approved, off-label use and clinical trial therapies. Results: 28 cases were enrolled: 18 aggressive NHL, 10 follicular lymphoma (FL). Molecular alterations were present in all cases. In aggressive B-cell NHL, CDKN2A/B gene cluster alterations were seen in 73% (8/11), while seen in only 1/7 T-cell lymphomas (TCL), and 1/10 FL. TP53 deletions were second most common genomic alterations in DLBCL (57%) and seen in 40% FL. JAK-STAT and ERBB pathways were altered in TCL (2/7 each). IGH-BCl-2 gene rearrangement were common in FL (70%), followed by MLL gene alterations (50%). Targetable mutations were present in 86% (24/28) of cases. A TT was recommended in all 24 cases, but received by 2 patients only. Remaining patients did not due to benefit from current therapy (10/24), ineligibility or lack of clinical trial (7/24) or interim clinical deterioration (5/24). Conclusions: Targetable mutations were identified in most cases of RR NHL with TT recommended for all cases. However, access to TT limits potential clinical benefit of molecular-based matching strategy. More studies are needed to assess impact on clinical outcomes.

scholarly journals The Mayo Clinic Biobank: A Building Block for Individualized Medicine

2013 ◽  
Vol 88 (9) ◽  
pp. 952-962 ◽  
Author(s):  
Janet E. Olson ◽  
Euijung Ryu ◽  
Kiley J. Johnson ◽  
Barbara A. Koenig ◽  
Karen J. Maschke ◽  
...  
Keyword(s):  
Building Block ◽  
Mayo Clinic ◽  
Individualized Medicine

scholarly journals A review of genomic data warehousing systems

2013 ◽  
Vol 15 (4) ◽  
pp. 471-483 ◽  
Author(s):  
T. Triplet ◽  
G. Butler
Keyword(s):  
Data Warehousing ◽  
Genomic Data ◽  
Warehousing Systems
Sign in / Sign up

Export Citation Format

Share Document